CCR2 on monocytes is downregulated with most inflammatory conditions in vitro and in vivo, including TNF-α or LPS treatment as well as in atherosclerotic plaques and multiple sclerosis lesions [41–43]. This evidence concerns the gene TNF and multiple sclerosis.